About: A systems approach to inflammation identifies therapeutic targets in SARS-CoV-2 infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A systems approach to inflammation identifies therapeutic targets in SARS-CoV-2 infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A systems approach to inflammation identifies therapeutic targets in SARS-CoV-2 infection
Creator	Kox, Matthijs Pickkers, Peter Giamarellos-Bourboulis, Evangelos Joosten, Leo Netea, Mihai Van De Veerdonk, Frank Van Der Meer, Jos De Mast, Quirijn Van Crevel, Reinout Frenzel, Tim Koenen, Hans Schouten, Jeroen Brüggemann, Roger Derde, Lennie Koeken, Valerie Kumar, Vinod Van Der Hoeven, Hans Dofferhoff, Anton Janssen, Nico Blaauw, Marc Boahen, Collins De Nooijer, Aline Grondman, Inge Hoefer, Imo Hoefsloot, Wouter Hoogerwerf, Jacobien Joosten, Irma Kerckhoffs, Angèle Kouijzer, Ilse Maas, Coen Matzaraki, Vasiliki Prof, Emeritus Reijers, Monique Schoneveld, Arjan Smeets, Ruben Toonen, Erik Van Den Heuvel, Michel Van Deuren, Marcel Veerman, Karin Willems, Loek
Source	MedRxiv
abstract	Background Infection with SARS-CoV-2 manifests itself as a mild respiratory tract infection in the majority of individuals, which progresses to a severe pneumonia and acute respiratory distress syndrome (ARDS) in 10-15% of patients. Inflammation plays a crucial role in the pathogenesis of ARDS, with immune dysregulation in severe COVID-19 leading to a hyperinflammatory response. A comprehensive understanding of the inflammatory process in COVID-19 is lacking. Methods In this prospective, multicenter observational study, patients with PCR-proven or clinically presumed COVID-19 admitted to the intensive care unit (ICU) or clinical wards were included. Demographic and clinical data were obtained and plasma was serially collected. Concentrations of IL-6, TNF-, complement components C3a, C3c and the terminal complement complex (TCC) were determined in plasma by ELISA. Additionally, 269 circulating biomarkers were assessed using targeted proteomics. Results were compared between ICU and non ICU patients. Findings A total of 119 (38 ICU and 91 non ICU) patients were included. IL-6 plasma concentrations were elevated in COVID-19 (ICU vs. non ICU, median 174.5 pg/ml [IQR 94.5-376.3 vs. 40.0 pg/ml [16.5-81.0]), whereas TNF- concentrations were relatively low and not different between ICU and non ICU patients (median 24.0 pg/ml [IQR 16.5-33.5] and 21.5 pg/ml [IQR 16.0-33.5], respectively). C3a and terminal complement complex (TCC) concentrations were significantly higher in ICU vs. non ICU patients (median 556.0 ng/ml [IQR 333.3-712.5]) vs. 266.5 ng/ml [IQR 191.5-384.0 for C3a and 4506 mAU/ml [IQR 3661-6595 vs. 3582 mAU/ml [IQR 2947-4300] for TCC) on the first day of blood sampling. Targeted proteomics demonstrated that IL-6 (logFC 2.2), several chemokines and hepatocyte growth factor (logFC 1.4) were significantly upregulated in ICU vs. non ICU patients. In contrast, stem cell factor was significantly downregulated (logFC -1.3) in ICU vs. non ICU patients, as were DPP4 (logFC -0.4) and protein C inhibitor (log FC -1.0), the latter two factors also being involved in the regulation of the kinin-kallikrein pathway. Unsupervised clustering pointed towards a homogeneous pathogenetic mechanism in the majority of patients infected with SARS-CoV-2, with patient clustering mainly based on disease severity. Interpretation We identified important pathways involved in dysregulation of inflammation in patients with severe COVID-19, including the IL-6, complement system and kinin-kallikrein pathways. Our findings may aid the development of new approaches to host-directed therapy.
has issue date	2020-05-24(xsd:dateTime)
bibo:doi	10.1101/2020.05.23.20110916
has license	medrxiv
sha1sum (hex)	16d968b6b5e6b3b80c3571a30d356a2cac3b9f76
schema:url	https://doi.org/10.1101/2020.05.23.20110916
resource representing a document's title	A systems approach to inflammation identifies therapeutic targets in SARS-CoV-2 infection
resource representing a document's body	covid:16d968b6b5e6b3b80c3571a30d356a2cac3b9f76#body_text
is schema:about of	named entity 'inflammation' named entity 'BASED' named entity 'HOMOGENEOUS' named entity 'INVOLVED' named entity 'POINTED' named entity 'DISEASE SEVERITY' covid:arg/16d968b6b5e6b3b80c3571a30d356a2cac3b9f76 named entity 'clustering' named entity 'patients' named entity 'disease' named entity 'pathogenetic' named entity 'systems approach' named entity 'SARS' named entity 'infection' named entity 'real-time PCR' named entity 'bradykinin' named entity 'COVID-19' named entity 'hyperinflammation' named entity 'lymphopenia' named entity 'severe infections' named entity 'covariate' named entity 'ACE' named entity 'TNF-α' named entity 'COVID' named entity 'immune dysregulation' named entity 'PCR' named entity 'preprint' named entity 'infection' named entity 'PCR' named entity 'plasma kallikrein' named entity 'cytokine' named entity 'HSCs' named entity 'C3a' named entity 'bradykinin' named entity 'peer review' named entity 'medRxiv' named entity 'preprint' named entity 'acute respiratory distress syndrome' named entity 'infectious diseases' named entity 'computed tomography' named entity 'IL-6' named entity 'C3a' named entity 'fibrosis' named entity 'lung' named entity 'ICU' named entity 'cytokine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software